Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye



Status:Completed
Conditions:Healthy Studies, Ocular
Therapuetic Areas:Ophthalmology, Other
Healthy:No
Age Range:18 - Any
Updated:7/15/2016
Start Date:June 2015
End Date:March 2016

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

This study will examine the safety, tolerability, and systemic pharmacokinetics of up to 3
different concentrations of AGN-232411 topical ophthalmic solution in healthy participants
and participants with dry eye.


Inclusion criteria:

Stage 1

-Healthy participants.

Stage 2 -Participants with the symptoms of dry eye disease.

Exclusion criteria:

Stage 1

-Known allergies or sensitivities to study medications, fluorescein, or lissamine green

Stage 2

- Known allergies or sensitivities to study medications, fluorescein, or lissamine
green

- Allergic ocular disease, ocular trauma, corneal erosions or ulcers, or uveitis within
the previous 12 months

- History of any ocular surgery within the previous 12 months.
We found this trial at
3
sites
Sall Research Center
Artesia, California 90701
?
mi
from
Artesia, CA
Click here to add this to my saved trials
Lugene Eye Institute
Glendale, California 91205
?
mi
from
Glendale, CA
Click here to add this to my saved trials
Montebello Medical Center, Inc.
Montebello, California 90640
?
mi
from
Montebello, CA
Click here to add this to my saved trials